Inhibition of granulocyte migration by tiotropium bromide [PDF]
Respiratory Research, 2011 Study objectives Neutrophil influx into the airways is an important mechanism in the pathophysiology of the inflammatory process in the airways of patients with chronic obstructive pulmonary disease (COPD).
Randerath Winfried J +2 more
doaj +12 more sources
Tiotropium bromide as adjunct therapy in children with asthma: a clinical experience [PDF]
Allergy, Asthma & Clinical Immunology, 2021 Background The Global Initiative for Asthma has only recently added tiotropium bromide as adjunct controller therapy in severe asthma (Step 4 or 5) in adults (2015) and children (2019). Although not yet approved for pediatric use by Health Canada, it has
Zainab Ridha +6 more
doaj +7 more sources
Skin reaction to inhaled tiotropium bromide: a case report [PDF]
Journal of Medical Case Reports, 2011 Introduction Systemic reactions to inhaled drugs are rare. To the best of our knowledge, we report the first case of generalized itching related to the use of tiotropium bromide, a long acting inhaled anti-cholinergic agent commonly used to treat chronic
Megali Raffaella +3 more
doaj +5 more sources
Expression of Muscarinic Receptors and the Effect of Tiotropium Bromide in Aged Mouse Model of Chronic Asthma [PDF]
Tuberculosis and Respiratory Diseases, 2019 Background Efficacy and safety of tiotropium bromide, a muscarinic receptor antagonist, in treatment of asthma have been reported. However, its effect on airway remodeling in chronic asthma of the elderly has not been clearly verified.
Ji Young Kang, M.D., Ph.D. +6 more
doaj +4 more sources
Tiotropium bromide: an update. [PDF]
Open Respir Med J, 2009 Tiotropium bromide is a once-daily inhaled anticholinergic bronchodilator. It works by blocking the muscarinic receptors in airway smooth muscle. Tiotropium has a wide therapeutic margin, due to its poor gastrointestinal absorption and its very low systemic bioavailability. The drug is mainly indicated in COPD patients.
Heredia JL.
europepmc +6 more sources
Legal demands of the tiotropium bromide for treatment of chronic obstructive pulmonary disease and their financial impact for the State of Paraná, Brazil [PDF]
Einstein (São Paulo), 2020 Objective To analyze the legal demands of tiotropium bromide to treat chronic obstructive pulmonary disease. Methods We included secondary data from the pharmaceutical care management systems made available by the Paraná State Drug Center.
Renata Szpak +4 more
doaj +4 more sources
A placebo-controlled, crossover trial to investigate the efficacy of tiotropium bromide or placebo added to usual care in stable symptomatic post-hematopoietic stem cell transplantation (HSCT) bronchiolitis obliterans syndrome (BOS) [PDF]
TrialsBackground Despite the fundamental progress in hematopoietic stem cell transplant, this treatment is also associated with complications. Graft-versus-host disease is a possible complication of HSCT.
Naeemeh Dini +6 more
doaj +4 more sources
Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside. [PDF]
Multidiscip Respir Med, 2017 After publication of the Review article it was brought to our attention that the sentence at the bottom of the section entitled Tiotropium bromide must be corrected as follows: “Following positive large efficacy and safety trials in asthma, in 2014 the European Medicines Agency has extended the indication of tiotropium Respimat®....
Radovanovic D +3 more
europepmc +7 more sources
Tiotropium Bromide Has a More Potent Effect Than Corticosteroid in the Acute Neutrophilic Asthma Mouse Model [PDF]
Tuberculosis and Respiratory Diseases, 2022 Background Neutrophilic asthma (NeuA) is usually resistant to corticosteroids. Tiotropium bromide (TIO) is a bronchodilator that is used as an add-on therapy to inhaled corticosteroid and long-acting β2 agonist in asthma treatment.
Tai Joon An +3 more
doaj +2 more sources
Suppression of IL-8 production from airway cells by tiotropium bromide in vitro
International Journal of COPD, 2011 Isao Suzaki1, Kazuhito Asano2, Yusuke Shikama3, Taisuke Hamasaki1, Ayako Kanei1, Harumi Suzaki11Department of Otorhinolaryngology, School of Medicine, Showa University, Tokyo, Japan; 2Division of Physiology, School of Nursing and Rehabilitation Sciences,
Suzaki I +5 more
doaj +4 more sources